氨溴索对慢性阻塞性肺疾病急性加重期气道炎性反应因子的影响

目的:观察氨溴索对慢性阻塞性肺疾病急性加重期(AECOPD)气道炎性反应因子的影响。方法:选择收治的AE-COPD患者50例,随机分为治疗组和对照组,均进行解痉、平喘、抗感染及吸氧等综合治疗,治疗组加用盐酸氨溴索注射液30 mg,加入5%葡萄糖注射液250 m l,静脉滴注,2次/d,7 d为1个疗程,2个疗程后比较两组患者肺功能及气道炎性反应因子的变化情况。结果:治疗后,两组患者FVC、FEV1、FEV1/FVC%等肺功能指标均较治疗前有明显改善(P<0.05),治疗组患者FVC、FEV1、FEV1/FVC%等肺功能指标与对照组比较差异有统计学意义(P<0.05);两组患者血清中IL-4、IL-8、TNF-α等指标水平均较治疗前明显下降(P<0.05);治疗组患者血清中IL-4、IL-8、TNF-α等指标水平显著降低,与对照组的差异具有统计学意义(P<0.05)。结论:氨溴索治疗AECOPD的疗效确切,可明显降低AECOPD患者血清中IL-4、IL-8、TNF-α等气道炎性反应因子水平。

Impact of ambroxol on inflammatory factors in patients with AECOPD

Objective To observe the impact of ambroxol on inflammatory factors in patients with AECOPD.Method Total 50 patients with AECOPD were randomly divided into the treatment group and the control group,all the patients were treated with spasmolysis,asthma,anti-infection and oxygen inhalation.The patients of the treatment group were treated with ambroxol hydrochloride injection 30 mg,5% glucose 250 ml intravenous injection on the basis of the conventional treatment,2 times/d.The efficacy and changes in lung function and inflammatory factors were compared.Results The lung function indexes such as FVC,FEV1,FEV1/FVC% and inflammatory factors such as IL-4,IL-8 and TNF-α of patients in the two groups were improved significantly compared with that of before treatment（P0.05）,and the magnitude of the treatment group was improved more significantly than the control group（P0.05）.Conclusion Ambroxol has obvious curative effect in treating patients with AECOPD,and can decrease the levels of inflammatory factors.